President and Chief Executive Officer
Duke Rohlen is the co-founder, President and Chief Executive Officer of the company. Mr. Rohlen previously served as a senior executive at FoxHollow Technologies, a leading endovascular device company specializing in the treatment of vascular disease. Prior to working at FoxHollow, Mr. Rohlen held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners. Mr. Rohlen is a member of the Board of Directors for CV Ingenuity, d3dc Corp., Nasoform Inc., and Mucosal Solutions, Inc. He received a B.A. from Stanford University and an M.B.A. from Harvard Business School.
Chief Financial Officer
Doug Koo has served as Chief Financial Officer of CV Ingenuity, Corp. since the inception of the company in 2008. Mr. Koo has also served as Chief Financial Officer of companies in several industries including mobile software for medical device companies, mobile entertainment, healthcare services, systems integration, and internet commerce. Mr. Koo has also held Managing Director and EIR positions with venture and advisory firms. Mr. Koo is a member of the Board of Directors for Bear Data Systems, MVRx and d3dc Corp. He received a B.A. from University of California, San Diego and an M.B.A. from Stanford University.
Philippe Marco, MD
Chief Operating Officer
Philippe Marco, M.D., has been CV Ingenuity's Chief Operating Officer since 2010. Dr. Marco spent the past 18 years working on development of medical devices in the interventional cardiovascular field. Prior to CVI, Dr. Marco held various operational and leadership positions at Xtent Inc., Abbott Vascular Devices (Abbott Laboratories) and Perclose Inc. Dr. Marco has contributed to numerous successful clinical evaluations and market approvals of coronary and endovascular products. Dr. Marco holds an MD from University of Toulouse (France) Medical School and completed his internal medicine and clinical pathology training at University of Limoges (France) Medical School.
Patrick H. Ruane, Ph.D
Vice President of Research and Development
Patrick H. Ruane, Ph.D., is the Vice President of Research and Development for CV Ingenuity. Patrick joined CVI in October 2010. He has held various R&D positions at several medical device companies over the past 10 years, including Xtent Inc., Cook Group and Gambro BCT. He received his primary degrees in Chemistry from The Galway-Mayo Institute of Technology and Trinity College Dublin, his Ph.D. from University College Dublin and Post-Docs at University of Toronto and The Johns Hopkins University and has published extensively in both the academic and patent literature.
Vice President of Quality Assurance & Regulatory Affairs
Cathy Mantor joined CVI in October, 2010. Prior to CVI, she held managerial and operational positions in Quality Assurance, Regulatory Affairs, Quality Engineering, Regulatory Compliance, Supplier Quality and Manufacturing with Xtent Incorporated, Arthrocare Corporation, General Surgical Innovations, Origin Medsytems, Lifescan, and Syva Company as well as general partnership with Chansu Consulting. Cathy obtained her Bachelor of Science degree in Physiology from the University of California, Davis and holds American Society of Quality certificates in Quality Management, Quality Auditing, and Quality Engineering.
Vice President of Operations
Mark Bishop joined CVI in January 2012 as their Vice President of Operations. Mr. Bishop brings over 24 years of medical device experience in Engineering, Operations, Quality and Regulatory. Prior to joining CVI, Mr. Bishop was the Vice President of Quality and Regulatory at Acclarent, Inc., a leading medical device company specializing in minimally invasive technology for ENT. Prior to Acclarent, Mr. Bishop was Director of Engineering at Abbott Vascular Devices and has held management and engineering positions at Perclose, Guidant and Devices for Vascular Intervention. He has a B.S. in Mechanical Engineering from California Polytechnic Institute, San Luis Obispo.
Gene Michal is a co-founder and Scientific Advisor for the company. Mr. Michal previously served as a research scientist at Advanced Cardiovascular Systems, Guidant and Abbott Vascular, companies leading the field in the treatment of vascular disease. There he worked in the areas of coatings for medical devices, drug delivery technologies, and biomaterials for stem cell therapies. Several technologies achieved clinical and commercial success. Mr. Michal has over 30 issued US patents covering biomaterials and coatings for medical devices. He received a B.A. from the University of Chicago.
Matthew Pollman, M.D
Matthew Pollman, M.D., is the co-founder and Scientific Advisor for the company. Dr. Pollman is a cardiologist and cardiovascular molecular biologist with over 15 years of experience leading R&D initiatives in the biotechnology, diagnostics, and medical devices healthcare arenas. He has served as Medical Director for Abbott Vascular, directed the New Ventures organization for Guidant Corporation and led cardiovascular biology and personalized medicine initiatives at Millennium Pharmaceuticals. Dr. Pollman is a board member of the Global Cardiovascular Innovation Center's commercial advisory board at the Cleveland Clinic and serves on the Board of Directors for Merlot OrthopediX, Juventas Therapeutics and NaviGate Cardiac Structures. Dr. Pollman received his medical and research training at the University of California San Francisco, Stanford University and Brigham and Women's Hospital.
Allan Johnston, Ph.D.
Dr. Johnston is co-founder and managing director of Synergy Ventures II LP, Synergy Partners International, and Nikko Synergy Ventures LLC. From 1992 to 1996, Dr. Johnston was Principal at Berkeley International Capital Corporation in charge of private equity investments in medical technology companies, with primary focus in the medical device industry. From 1987 to 1992, Dr. Johnston was Program Manager at the Center for Medical Technology at SRI International, an international R&D institution in California. At SRI, he directed research projects, product development, and technical and business consulting activities for medical technology companies worldwide. Dr. Johnston has a Ph.D. in bioinorganic chemistry from the University of Guelph. He serves on the board of several private companies and is an outside director of Three Oaks Innovations, a company focused on commercialization of technology developed at the University of Prince Edward Island.
Robert W. Thomas
Robert W. Thomas currently serves as a member of the Board of Directors for seven companies in the life sciences field, as well as serving on the board for several non-profit organizations. Mr. Thomas served as the President & CEO and a member of the board of FoxHollow Technologies from May 2000 until January 2006. Mr. Thomas was the CEO that led the company from 12 employees in startup mode, and through a successful public offering with over a $1B market capitalization. From April 1999 until May 2000, Mr. Thomas served as FoxHollow's Vice President of Operations. From March 1998 until April 1999, Mr. Thomas served as Vice President, Operations for Conceptus. From March 1990 until February 1998, Mr. Thomas was a founder of TMP, Inc., a privately financed medical device startup company in Malvern, PA. VSI (now GE Healthcare) acquired TMP in September 1992, and Mr. Thomas stayed on as Vice President for the TMP division through February 1998. From November 1984 through March 1990, Mr. Thomas was a founder and held various managerial positions with Access Devices (acquired by Baxter Healthcare) in Bristol, PA and also worked with Corestates Bank from July 1983 through November 1984 in the Specialized Lending Division. Mr. Thomas received a B.A. in Economics from Ursinus College.
Dr. Justin Klein
Dr. Justin Klein is a venture capital investor with New Enterprise Associates, where he has focused on the healthcare sector since 2006. Previously, he worked in operations and finance at a large health system and at a law firm where he assisted life sciences companies on numerous licensing transactions, regulatory and corporate securities matters. In addition to serving as a director of CV Ingenuity, he is a board member at PhaseBio Pharmaceuticals, Ulthera, VertiFlex, and VytronUS, and is a board observer for Carticept Medical, ExploraMed, Moximed, Sensors for Medicine and Science, TriVascular, and Vibrynt. Dr. Klein concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He received his AB in Economics and his BS in Biological Anthropology and Anatomy from Duke University.
Ryan Drant joined NEA in 1996, and became a General Partner in 2004. He specializes in healthcare investments in the medical device, healthcare information technology and specialty pharma sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, ExploraMed III, Intrinsic Therapeutics, Neotract, PatientKeeper, Simplex Healthcare, Spine Wave, TriVascular and Vibrynt. Ryan also serves on the board of the Medical Device Manufacturers Association. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan), FoxHollow Technologies (acquired by EV3, now Covidien), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation, now Hologic), and Ryan co-led NEA's investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.
Louis A. Cannon, MD
Louis A. Cannon, MD, FACA, FCCP, FACC, FACP, is a former Judith Volkman scholar in residence who has been repeatedly honored as one of "America's Top Interventional Cardiologists." He is the President of the Cardiac and Vascular Research Center of Northern Michigan. He has over 125 medical publications, as well as United States medical device patents, and is the Founder and Senior Managing Director of BioStar Ventures. Dr. Cannon serves on the strategic advisory boards for such Fortune 500 companies as Medtronic, Abbott, and Boston Scientific, as well as many early developing medical technologies companies. He currently serves on the Board of Directors of CardioVascular Ingenuity and Kona Medical. Dr. Cannon has participated in the startup and subsequent development of a multitude of developing bio-technological, or emerging healthcare companies and has served as the National or International Principal Investigator for landmark cardiovascular studies. He has assisted in performing the First-In-Man percutaneous Aortic Valve procedures in Paraguay and served as Chairman of the Board of AorTx, Inc, which was successfully acquired by a publicly traded company. Dr. Cannon was instrumental as Chairman of the Scientific Advisory Board of Setagon which was acquired by a Fortune 100 company. Dr. Cannon practices interventional cardiology with Michigan Heart & Vascular Specialists and is the Program Director of the Heart & Vascular Institute at Northern Michigan Regional Hospital in Petoskey, Michigan.
William M. Facteau
William Facteau is the Vice Chairman of ExploraMed Development, LLC, a medical device incubator based on the West Coast. In addition he serves as an Entrepreneur in Residence with New Enterprise Associates. He also sits on the Board of Directors of ExploraMed Development LLC, NeoTract, Inc., and Earlens Corporation. Prior to this, Mr. Facteau joined Johnson and Johnson in January 2010 after Ethicon acquired Acclarent for $785 million in cash where he served as the Worldwide President of Acclarent, a dedicated stand-alone ENT division of Ethicon. Prior to the acquisition, Mr. Facteau joined Acclarent and its founders in 2004 as the President, CEO, and a member of the Board of Directors. Under Mr. Facteau's leadership, the company went from concept to acquisition in 5 ½ years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable. Prior to joining Acclarent, Mr. Facteau was the General Manager of the Endovascular Division at Abbott Vascular, where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. Mr. Facteau joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was the Area Sales Director. From July 1993 to April 1998, Mr. Facteau worked in a number of sales and sales management positions at United States Surgical Corporation. Mr. Facteau received his B.A. in Political Science from the University of Connecticut, and is a named inventor on seven issued patents.